Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05733767 · ClinicalTrials.gov registry record · Phase 2
Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study
A Phase 2 study of Smoking Cessation and Cardiopulmonary Disease, sponsored by Baystate Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 424
- Enrollment target
- 1
- Study location
NCT05733767 is a Phase 2 study of Smoking Cessation and Cardiopulmonary Disease that is actively recruiting participants, run by Baystate Medical Center. The registered enrollment target is 424 participants, below the 472-participant average among 188 other Smoking Cessation trials with a reported enrollment target (10% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05733767, a Phase 2 study of Smoking Cessation and Cardiopulmonary Disease, is actively recruiting participants, sponsored by Baystate Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 424 participants
- Enrollment target
- 1
- Study location
Study Summary
Tobacco use remains the leading cause of death in the United States and contributes to more than 7 million hospitalizations annually. Being admitted to the hospital offers the perfect opportunity to support smoking cessation. Patients are motivated to quit because of their current illness and societal guidelines recommend clinicians should counsel patients and prescribe smoking cessation pharmacotherapy (SCP) to virtually all smokers. However, only 22% of patients are prescribed SCP while hospitalized, and only 1% are prescribed medications compatible with current guidelines. This failure is part of the reason 70-80% of hospitalized smokers eventually relapse. The relapse typically occurs within a few days of hospital discharge - well before outpatient follow-up can occur. The investigators aim to improve smoking cessation treatment and guideline adherence by utilizing the opportunity that hospitalization provides. The investigators have created a tobacco treatment team (T3) to overcome physicians' and patients' low use of current guideline smoking cessation medications. The team members are trained in tobacco treatment and will be led by a nurse practitioner (NPT3). The team will work together and 1) prescribe individually tailored and guideline-concordant SCP; 2) counsel and motivate patients to use SCP properly; and 3) manage a mobile phone-based text-messaging system to keep patients motivated and adherent to SCP. Our preliminary data suggest that such an approach is workable and acceptable to patients, physicians, and hospital administrators. The investigators will recruit 424 patients in the hospital who smoke with cardiopulmonary disease. These patients will be randomized to receive either usual care or personalized care with the NPT3 team. The investigators will compare rates of guideline-concordant SCP use at 1 week and exhaled carbon monoxide (eCO) verified smoking cessation at 6 months between patients randomized to the NPT3 team vs. usual care. The i
Conditions Studied
Interventions
- OTHER Enhanced Usual Care (EUC)
- OTHER Nurse Practitioner Tobacco Treatment Team (NPT3)
Study Locations (1)
Massachusetts
- Baystate Medical Center - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 424 participants |
| Start Date | 2022-11-03 |
| Est. Completion | 2027-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05733767
The ClinicalTrials.gov registry entry for NCT05733767 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 424 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 472-participant average among 188 other Smoking Cessation trials with a reported enrollment target (10% lower). The listed sponsor is Baystate Medical Center, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which Enhanced Usual Care (EUC) is the first listed.
NCT05733767 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05733767 about?
NCT05733767 is a clinical study titled "Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study". Tobacco use remains the leading cause of death in the United States and contributes to more than 7 million hospitalizations annually. Being admitted to the hospital offers the perfect opportunity to support smoking cessation. Patients are motivated to quit because of their current illness and societ...
What is the current status of trial NCT05733767?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 424 participants. The study started on 2022-11-03. Estimated completion is 2027-12-30.
What conditions does trial NCT05733767 study?
This clinical trial studies the following conditions: Smoking Cessation, Cardiopulmonary Disease, Inpatient.
What interventions are being tested in trial NCT05733767?
The interventions under investigation include: Enhanced Usual Care (EUC) (OTHER), Nurse Practitioner Tobacco Treatment Team (NPT3) (OTHER).
Who is sponsoring clinical trial NCT05733767?
This trial is sponsored by Baystate Medical Center, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05733767 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
RECRUITING · Phase 2
-
Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate
COMPLETED · Phase 2
-
Treating Smokers With Mental Illness
COMPLETED · Phase 2
-
Suvorexant to Reduce Symptoms of Nicotine Use
COMPLETED · Phase 2
-
Pharmacogenetics, Emotional Reactivity and Smoking
COMPLETED · Phase 2
-
Provoked Craving Relief Study by NRT
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.